HRP20220429T1 - Novi antagonisti receptora bradikinina b2 - Google Patents
Novi antagonisti receptora bradikinina b2 Download PDFInfo
- Publication number
- HRP20220429T1 HRP20220429T1 HRP20220429TT HRP20220429T HRP20220429T1 HR P20220429 T1 HRP20220429 T1 HR P20220429T1 HR P20220429T T HRP20220429T T HR P20220429TT HR P20220429 T HRP20220429 T HR P20220429T HR P20220429 T1 HRP20220429 T1 HR P20220429T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- atom
- atoms
- image
- compound
- Prior art date
Links
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 title 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000004431 deuterium atom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- -1 tetrahydro-2H-pyranyl Chemical group 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Spoj opće formule (I):
[image]
ili njegova sol, naznačen time što
A predstavlja skupinu:
[image]
A1 je N, ili CH;
A2 je N, ili C-RA2;
A3 je N, ili C-RA3;
A4 je NH, O, ili S;
A5 je N-RA5;
RA1 predstavlja vodikov atom ili metilnu skupinu;
RA2 i RA3 svaki, neovisno jedan o drugom, predstavlja vodikov atom, atom halogena, OH, CN, NH2; (C1-C3)alkil, koji može biti supstituiran s jednom ili više, identičnih ili različitih, skupina odabranih od atoma halogena, OH, =O, i NH2; (C1-C3)alkoksi, koja može biti supstituirana s jednom ili više, identičnih ili različitih, skupina odabranih od atoma halogena, OH, =O, i NH2; (C2-C5)alkoksialkil, koja može biti supstituirana s jednom ili više, identičnih ili različitih, skupina odabranih od atoma halogena, OH, =O, i NH2; C(O)NRB1RB2; ili NRB1RB2;
RB1, RB2 i RA5 svaki, neovisno jedan o drugom, predstavlja vodikov atom ili skupinu (C1-C3)alkil, koja može biti supstituirana s jednom ili više, identičnih ili različitih, skupina odabranih od atoma halogena, OH, =O, i NH2;
R1 predstavlja skupinu (C1-C3)alkil ili (C2-C5)alkoksialkil, koja alkilna skupina ili alkoksialkilna skupina može biti supstituirana s jednom ili više, identičnih ili različitih, skupina odabranih od atoma deuterija, atoma halogena, OH, =O, i NH2;
R2 predstavlja vodikov atom ili atom deuterija;
R3 predstavlja vodikov atom, skupinu (C1-C3)alkil, ili skupinu (C1-C3)haloalkil;
E predstavlja CRE1RE2RE3 ili Hce;
Hce predstavlja mono- ili biciklički, djelomično nezasićeni ili aromatski heterocikl koji ima 3 do 10 C atoma i 1 do 4 heteroatoma koji su svaki, neovisno jedan o drugom, odabrani od N, O ili S, koji heterocikl je nesupstituiran ili može biti mono-, di- ili trisupstituiran, u svakoj prilici neovisno, s atomom halogena, OH, G, NRC1RC2 i/ili =O;
RC1 i RC2 svaki, neovisno jedan o drugom, predstavlja vodikov atom ili skupinu (C1-C3)alkil;
G predstavlja skupinu (C1-C6)alkil, u kojoj 1 do 7 H atoma može, u svakoj prilici neovisno, biti zamijenjeno s atomom halogena, ORG1, CN, NRG2RG3 ili (C3-C6)cikloalkil, i/ili u kojoj se jedna CH2 skupina, ili dvije nesusjedne CH2 skupine, mogu zamijeniti sa O, C(O), OC(O), C(O)O, C(O)NH, NH, S, SO, SO2 i/ili sa skupinom CH=CH;
RG1, RG2, i RG3 svaki, neovisno jedan o drugom, predstavlja vodikov atom, skupinu (C1-C4)alkil, (C1-C4) haloalkil, (C1-C4) hidroksialkil, (C1-C4) heteroalkil, ili (C3-C6) cikloalkil;
RE1 i RE2 svaki, neovisno jedan o drugom, predstavlja vodikov atom, atom halogena, ili G; ili RE1 i RE2 uzeti zajedno tvore =O ili Cyc;
RE3 predstavlja vodikov atom, atom halogena, G, OG ili OH; i
Cyc predstavlja mono- ili bicikličku, zasićenu ili djelomično nezasićenu 3- do 10-članu cikloalkilnu skupinu ili 4- do 10-članu heterocikloalkilnu skupinu koja ima 1 do 3 heteroatoma koji su svaki, neovisno jedan o drugom, odabrani od N, O ili S, koja cikloalkilna ili heterocikloalkilna skupina je nesupstituirana ili može biti mono-, di-, tri-, ili tetrasupstituirana, u svakoj prilici neovisno, s atomom halogena, OH, G, NRC1RC2 i/ili =O.
2. Spoj ili sol prema patentnom zahtjevu 1, naznačen time što R1 predstavlja skupinu (C1-C2)alkil ili skupinu (C2-C4)alkoksialkil, navedena alkilna skupina ili alkoksialkilna skupina može biti supstituirana s jednom ili više, identičnih ili različitih, skupina odabranih od atoma deuterija, atoma halogena, i OH.
3. Spoj ili sol prema patentnom zahtjevu 1 ili 2, naznačen time što R3 predstavlja vodikov atom ili metilnu skupinu.
4. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što E je CRE1RE2RE3; RE1 predstavlja vodikov atom, fluorov atom, metil ili etil; i svaki RE2 i RE3 je definiran kao u zahtjevu 1.
5. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što RE2 predstavlja vodikov atom, fluorov atom, skupinu (C1-C6)alkil, poželjno skupinu (C1-C3)alkil, u kojoj 1 do 4 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, ili NRC1RC2; skupinu (C1-C6)alkoksi, poželjno skupinu (C1-C3)alkoksi, u kojoj 1 do 4 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, NRC1RC2 ili ciklopropilom; ili skupinu (C2-C5)alkoksialkil, u kojoj 1 do 5 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, NRC1RC2 ili ciklopropilom; i svaki RC1 i RC2 je definiran kao u zahtjevu 1.
6. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što RE3 predstavlja vodikov atom, fluorov atom, OH, skupinu (C1-C6)alkil, poželjno skupinu (C1-C3)alkil, u kojoj 1 do 5 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, ili NRC1RC2; skupinu (C1-C6)alkoksi, u kojoj 1 do 5 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, NRC1RC2 ili ciklopropil; skupinu (C2-C5)alkoksialkil, u kojoj 1 do 5 H atoma mogu, u svakoj prilici neovisno, biti zamijenjeni atomom fluora, OH, =O, NRC1RC2 ili ciklopropilom; i svaki RC1 i RC2 je definiran kao u zahtjevu 1.
7. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što E je CRE1RE2RE3; i RE1 i RE2 su uzeti zajedno tako da tvore =O ili Cyc, pri čemu je Cyc odabran iz niza koji čine ciklopropil, ciklobutil, ciklopentil, oksetanil, tetrahidrofuranil, tetrahidro-2H-piranil, 1,3-dioksolanil, morfolinil, azetidinil pirolidinil, piperidinil, piperazinil, (imidazolidin-2-on)il i (oksazolidin-2-on)il, te je supstituiran ili može biti mono-, di- ili trisupstituiran, u svakoj prilici neovisno, s atomom halogena, OH, G, NRC1RC2 i/ili =O; i svaki od RC1, RC2 i RE3 je definiran kao u zahtjevu 1.
8. Spoj ili sol prema patentnom zahtjevu 7, naznačen time što RE3 predstavlja vodikov atom, fluorov atom, OH ili skupinu (C1-C3)alkil.
9. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što E je Hce, i Hce predstavlja monociklički, djelomično nezasićeni ili aromatski heterocikl koji ima 3 do 5 C atoma i 1 do 3 N atom(a); 3 do 5 C atoma, 1-2 N atom(a) i 1 O atom; ili 3 do 5 C atoma, 1-2 N atom(a) i 1 S atom; koji heterocikl je nesupstituiran ili može biti mono-, di- ili trisupstituiran, u svakoj prilici neovisno, s atomom halogena, OH, (C1-C3)alkilom, (C1-C3)haloalkilom, (C1-C3)alkoksi, (C1-C3)haloalkoksi i/ili =O.
10. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 6, i 9, naznačen time što E predstavlja skupinu:
[image]
[image]
[image]
[image]
[image]
11. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što je spoj odabran iz skupine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
12. Farmaceutski pripravak koji sadrži jedan ili više spojeva prema bilo kojem od patentnih zahtjeva 1 do 11 i, po izboru, najmanje jednu tvar nosača, pomoćnu tvar i/ili pomoćno sredstvo.
13. Farmaceutski pripravak prema patentnom zahtjevu 12, naznačen time što je farmaceutski pripravak formuliran kao aerosol, krema, gel, pilula, kapsula, sirup, otopina, transdermalni flaster ili uređaj za isporuku lijeka.
14. Kombinirani pripravak naznačen time što sadrži najmanje jedan spoj prema bilo kojem od zahtjeva 1 do 11 i najmanje jedan daljnji aktivni farmaceutski sastojak.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, farmaceutski pripravak prema zahtjevu 12, ili kombinirani pripravak prema zahtjevu 14 za upotrebu kao lijek.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203675 | 2017-11-24 | ||
| EP18818992.2A EP3713928B1 (en) | 2017-11-24 | 2018-11-23 | Novel bradykinin b2 receptor antagonists |
| PCT/EP2018/082338 WO2019101906A1 (en) | 2017-11-24 | 2018-11-23 | Novel bradykinin b2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220429T1 true HRP20220429T1 (hr) | 2022-05-27 |
Family
ID=60473364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220429TT HRP20220429T1 (hr) | 2017-11-24 | 2018-11-23 | Novi antagonisti receptora bradikinina b2 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10836748B2 (hr) |
| EP (2) | EP3998259A1 (hr) |
| JP (2) | JP7164619B2 (hr) |
| KR (1) | KR102413321B1 (hr) |
| CN (1) | CN111433196B (hr) |
| AR (1) | AR113839A1 (hr) |
| AU (1) | AU2018371186B2 (hr) |
| BR (1) | BR112020010298A2 (hr) |
| CA (1) | CA3082948A1 (hr) |
| CY (1) | CY1125348T1 (hr) |
| DK (1) | DK3713928T3 (hr) |
| EA (1) | EA202091256A1 (hr) |
| ES (1) | ES2908409T3 (hr) |
| HR (1) | HRP20220429T1 (hr) |
| HU (1) | HUE058217T2 (hr) |
| IL (1) | IL274883B2 (hr) |
| LT (1) | LT3713928T (hr) |
| MA (1) | MA50804B1 (hr) |
| MX (1) | MX2020005287A (hr) |
| NZ (1) | NZ764304A (hr) |
| PH (1) | PH12020550683A1 (hr) |
| PL (1) | PL3713928T3 (hr) |
| PT (1) | PT3713928T (hr) |
| RS (1) | RS63087B1 (hr) |
| SG (1) | SG11202004653TA (hr) |
| SI (1) | SI3713928T1 (hr) |
| TW (1) | TWI768156B (hr) |
| UY (1) | UY37981A (hr) |
| WO (1) | WO2019101906A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2908409T3 (es) | 2017-11-24 | 2022-04-29 | Pharvaris Netherlands B V | Antagonistas novedosos del receptor B2 de bradiquinina |
| AR118983A1 (es) | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| KR20230107269A (ko) | 2020-11-12 | 2023-07-14 | 파르바리스 게엠베하 | 혈관부종의 예방 및 치료 |
| WO2023012324A1 (en) | 2021-08-05 | 2023-02-09 | Pharvaris Gmbh | Solid form of a bradykinin b2-receptor antagonist |
| TW202320774A (zh) | 2021-08-05 | 2023-06-01 | 瑞士商帕法瑞斯有限責任公司 | 用於口服之舒緩肽ｂ２受體拮抗劑之基於脂質之組成物 |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
| WO2023180575A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| AU705883B2 (en) | 1994-10-27 | 1999-06-03 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused N-heretocycles as bradykinin antagonists |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| CZ20011417A3 (cs) | 1998-10-21 | 2001-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Sklovitá forma 8-(3-(N-((E)-3-(6-acetamidopyridin-3-yl)-akryloylglycyl)-N-methylamino)-2,6-dichlorbenzyloxy)-2-methylchinolinu |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| AU2001229580A1 (en) | 2000-01-18 | 2001-08-14 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| US6958349B2 (en) | 2002-04-10 | 2005-10-25 | Ortho-Mcneil Pharmaceuticals, Inc. | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| MX2015012650A (es) | 2013-03-14 | 2016-06-21 | Shire Human Genetic Therapies | Metodos para el tratamiento de angioedema mediado receptores debradicinina b2. |
| ES2908409T3 (es) | 2017-11-24 | 2022-04-29 | Pharvaris Netherlands B V | Antagonistas novedosos del receptor B2 de bradiquinina |
-
2018
- 2018-11-23 ES ES18818992T patent/ES2908409T3/es active Active
- 2018-11-23 LT LTEPPCT/EP2018/082338T patent/LT3713928T/lt unknown
- 2018-11-23 UY UY0001037981A patent/UY37981A/es unknown
- 2018-11-23 MX MX2020005287A patent/MX2020005287A/es unknown
- 2018-11-23 CN CN201880076162.XA patent/CN111433196B/zh active Active
- 2018-11-23 SG SG11202004653TA patent/SG11202004653TA/en unknown
- 2018-11-23 EP EP21213719.4A patent/EP3998259A1/en active Pending
- 2018-11-23 DK DK18818992.2T patent/DK3713928T3/da active
- 2018-11-23 AU AU2018371186A patent/AU2018371186B2/en active Active
- 2018-11-23 JP JP2020545875A patent/JP7164619B2/ja active Active
- 2018-11-23 PT PT188189922T patent/PT3713928T/pt unknown
- 2018-11-23 IL IL274883A patent/IL274883B2/en unknown
- 2018-11-23 AR ARP180103444A patent/AR113839A1/es unknown
- 2018-11-23 CA CA3082948A patent/CA3082948A1/en active Pending
- 2018-11-23 EP EP18818992.2A patent/EP3713928B1/en active Active
- 2018-11-23 WO PCT/EP2018/082338 patent/WO2019101906A1/en unknown
- 2018-11-23 RS RS20220335A patent/RS63087B1/sr unknown
- 2018-11-23 BR BR112020010298-9A patent/BR112020010298A2/pt unknown
- 2018-11-23 EA EA202091256A patent/EA202091256A1/ru unknown
- 2018-11-23 MA MA50804A patent/MA50804B1/fr unknown
- 2018-11-23 SI SI201830628T patent/SI3713928T1/sl unknown
- 2018-11-23 PL PL18818992T patent/PL3713928T3/pl unknown
- 2018-11-23 HU HUE18818992A patent/HUE058217T2/hu unknown
- 2018-11-23 NZ NZ764304A patent/NZ764304A/en unknown
- 2018-11-23 TW TW107141872A patent/TWI768156B/zh active
- 2018-11-23 HR HRP20220429TT patent/HRP20220429T1/hr unknown
- 2018-11-23 KR KR1020207017972A patent/KR102413321B1/ko active IP Right Grant
-
2020
- 2020-04-28 US US16/861,131 patent/US10836748B2/en active Active
- 2020-05-21 PH PH12020550683A patent/PH12020550683A1/en unknown
- 2020-09-25 US US17/033,347 patent/US11261173B2/en active Active
-
2022
- 2022-01-18 US US17/578,161 patent/US11820756B2/en active Active
- 2022-04-11 CY CY20221100272T patent/CY1125348T1/el unknown
- 2022-10-20 JP JP2022168473A patent/JP2023002701A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220429T1 (hr) | Novi antagonisti receptora bradikinina b2 | |
| ES2592404T3 (es) | Benzotienopirimidinas sustituidas | |
| HRP20191414T1 (hr) | Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori | |
| WO2019034692A1 (en) | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 | |
| JP2016510758A5 (hr) | ||
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| ES2623777T3 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| MX355164B (es) | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). | |
| CO6761374A2 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| MX2021004000A (es) | Derivados de piperidina. | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| BR112016027778A2 (pt) | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica | |
| PH12019502562A1 (en) | N-substituted indole derivatives | |
| MX355436B (es) | Sal novedosa de abexinostato, forma cristalina asociada, método de preparacion de la misma y las composiciones farmaceuticas que contienen la misma. | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos | |
| CA2891755C (en) | Substituted pyrido-piperazinone derivatives as gamma secretase modulators | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| HRP20211524T1 (hr) | Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju | |
| AR117006A1 (es) | Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| MX2019006939A (es) | Preparacion liquida parenteral que comprende compuesto de carbamato. | |
| PH12017500323B1 (en) | P38 map kinase inhibiting indanyl urea compounds |